AbCheck provides a unique source of therapeutic antibodies with one of the industry’s most versatile technology platforms. We provide high-quality drug candidates through discovery collaborations or strategic research partnerships based on flexible business terms including royalty-free agreements. We generate target specific human antibody domains which can be used in distinct therapeutic formats. AbCheck was founded in 2009 and is a spin-out of Affimed’s technology discovery platform. AbCheck is a wholly owned subsidiary of Affimed GmbH, a biopharmaceutical company developing highly targeted cancer immunotherapies.